JP2023541606A - 腎臓を保護しながらがんを治療するための方法 - Google Patents

腎臓を保護しながらがんを治療するための方法 Download PDF

Info

Publication number
JP2023541606A
JP2023541606A JP2023516137A JP2023516137A JP2023541606A JP 2023541606 A JP2023541606 A JP 2023541606A JP 2023516137 A JP2023516137 A JP 2023516137A JP 2023516137 A JP2023516137 A JP 2023516137A JP 2023541606 A JP2023541606 A JP 2023541606A
Authority
JP
Japan
Prior art keywords
iron
content
approximately
protoporphyrin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516137A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022056378A5 (https=
JP2023541606A5 (https=
Inventor
カイザー，ドナルド
ギエム，アルバロ
ゼーガー，リチャード
Original Assignee
レニバス・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レニバス・セラピューティクス・インコーポレイテッド filed Critical レニバス・セラピューティクス・インコーポレイテッド
Publication of JP2023541606A publication Critical patent/JP2023541606A/ja
Publication of JPWO2022056378A5 publication Critical patent/JPWO2022056378A5/ja
Publication of JP2023541606A5 publication Critical patent/JP2023541606A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023516137A 2020-09-11 2021-09-13 腎臓を保護しながらがんを治療するための方法 Pending JP2023541606A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062706829P 2020-09-11 2020-09-11
US62/706,829 2020-09-11
US202163158803P 2021-03-09 2021-03-09
US63/158,803 2021-03-09
PCT/US2021/050064 WO2022056378A1 (en) 2020-09-11 2021-09-13 Method for treating cancer with kidney protection

Publications (3)

Publication Number Publication Date
JP2023541606A true JP2023541606A (ja) 2023-10-03
JPWO2022056378A5 JPWO2022056378A5 (https=) 2024-09-20
JP2023541606A5 JP2023541606A5 (https=) 2024-09-20

Family

ID=80626052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516137A Pending JP2023541606A (ja) 2020-09-11 2021-09-13 腎臓を保護しながらがんを治療するための方法

Country Status (10)

Country Link
US (1) US20220079984A1 (https=)
EP (1) EP4210691A4 (https=)
JP (1) JP2023541606A (https=)
KR (1) KR20230112608A (https=)
CN (1) CN116348107A (https=)
AU (1) AU2021342291A1 (https=)
CA (1) CA3192411A1 (https=)
IL (1) IL301305A (https=)
MX (1) MX2023002929A (https=)
WO (1) WO2022056378A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118103047A (zh) 2021-08-27 2024-05-28 美国瑞根特有限公司 铁组合物及其制备和使用方法
JPWO2024253189A1 (https=) * 2023-06-09 2024-12-12

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015729A1 (en) * 1992-02-07 1993-08-19 Tsumura & Co. Side-effect alleviant
US20200277325A1 (en) * 2019-02-28 2020-09-03 Renibus Therapeutics, Inc. Novel iron compositions and methods of making and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6010696A (en) * 1995-06-10 1997-01-09 Vitra Pharmaceuticals Ltd Iron compounds, compositions, methods of making the same and uses thereof
WO2005094202A2 (en) * 2004-03-16 2005-10-13 Navinta, Llc Iron sucrose complexes and method of manufacture thereof
DK2262520T3 (en) * 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
SI3200582T1 (sl) * 2014-09-29 2024-04-30 Fred Hutchinson Cancer Center Sestave, kompleti in metode za indukcijo pridobljene citorezistence z uporabo induktorjev stresnih proteinov
AU2016366668A1 (en) * 2015-12-11 2018-05-31 Fred Hutchinson Cancer Research Center Peptides for renal therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015729A1 (en) * 1992-02-07 1993-08-19 Tsumura & Co. Side-effect alleviant
US20200277325A1 (en) * 2019-02-28 2020-09-03 Renibus Therapeutics, Inc. Novel iron compositions and methods of making and using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RICHARD A ZAGER, ET AL.: ""Iron sucrose ('RBT-3') activates the hepatic and renal HAMP1 gene, evoking renal hepcidin loading a", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 2021, Vol.36, No.3, JPN6025040702, 2 December 2020 (2020-12-02), pages 465 - 474, ISSN: 0005703114 *
RICHARD A. ZAGER, ET AL.: ""Combined iron sucrose and protoporphyrin treatment protects against ischemic and toxin-mediated acu", KIDNEY INTERNATIONAL, vol. 90, no. 1, JPN6025040704, 2016, pages 67 - 76, ISSN: 0005703115 *
YOUNG TAE KIM, ET AL.: ""Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cance", GYNECOLOGIC ONCOLOGY, vol. 105, no. 1, JPN6025040703, 2007, pages 199 - 204, ISSN: 0005703116 *

Also Published As

Publication number Publication date
IL301305A (en) 2023-05-01
EP4210691A4 (en) 2025-02-26
MX2023002929A (es) 2023-05-22
BR112023004583A2 (pt) 2023-04-11
WO2022056378A1 (en) 2022-03-17
AU2021342291A1 (en) 2023-04-20
EP4210691A1 (en) 2023-07-19
CN116348107A (zh) 2023-06-27
US20220079984A1 (en) 2022-03-17
KR20230112608A (ko) 2023-07-27
CA3192411A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
US8946169B2 (en) SPARC and methods of use thereof
EP1755653B1 (en) Treatment methods utilizing albumin-binding proteins as targets
JP2023541606A (ja) 腎臓を保護しながらがんを治療するための方法
JP6548803B1 (ja) 腎障害の抑制におけるシラスタチンの利用
Samal et al. Administration of nitrite after chlorine gas exposure prevents lung injury: effect of administration modality
US20250011470A1 (en) Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
CN112336736A (zh) 开环异落叶松脂素二葡糖苷(sdg)和相关化合物用于防护辐射和化学损害的用途
Zhang et al. Neuritin promotes autophagic flux by inhibiting the cGAS-STING pathway to alleviate brain injury after subarachnoid haemorrhage
Chmielewska et al. Expression of metallothioneins I and II in kidney of doxorubicin-treated rats
CN113382742A (zh) 工程化的鞭毛蛋白来源的组合物和用途
HK40095700A (zh) 通过肾脏保护来治疗癌症的方法
BR112023004583B1 (pt) Uso de uma composição farmacêutica com uma quantidade de composição de sacarose de ferro para proteger o rim durante a quimioterapia do câncer e durante imageamento de radiocontraste
Yamashita et al. Inhibitory effect of α-tocopherol on methylmercury-induced oxidative steress
Villanueva et al. Hepatic and extrahepatic synthesis and disposition of dinitrophenyl-S-glutathione in bile duct-ligated rats
US20210299270A1 (en) Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
Stefanowicz et al. Nephrotoxicity of platinum derivatives in children–a review of the literature
JP2022545429A (ja) がん治療のための化学療法剤とα－ラクトグロブリン－オレイン酸複合体との組合せ
US20250352654A1 (en) Pharmaceutical agent conjugates to modulate macrophage and inflammatory functions and uses thereof
US20220273703A1 (en) Nrf2 activation for treatment of nephrogenic diabetes insipidus
CN110869019A (zh) 用于治疗血脂异常的烟酰胺
WO2022019235A1 (ja) 腎障害の抑制におけるビタミンｂ１２の利用
Riordan et al. Poisoning in childhood
WO2026021587A1 (zh) 制备高同质性的抗体-药物缀合物的方法
Molitoris Therapeutic alpha-1-microglobulin ameliorates kidney ischemia reperfusion injury
HK40015305A (en) Nicotinamide for treating dyslipidemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331